Mark Kupersmith, MD

img_Mark Kupersmith
CLINICAL PROFESSOR | Ophthalmology
CLINICAL PROFESSOR | Neurosurgery
CLINICAL PROFESSOR | Neurology
Research Topics
MRI, Neuroscience, Vision
New topic

I have serve as Chair of the planning committee for NORDIC and directed NORDIC (February 2009-present), fulfilling all of the obligations outlined in NORDIC policies and in the Idiopathic Intracranial Hypertension Treatment Trial, the LIIHTT and for proposed studies, HIS and SiihTT. I intend to continue in the same capacity now as Director of the Enrollment and Resource Centers, administratively integrating studies, sites, investigators, reading centers, Data Coordinating and Biostatistical Center, managing sites and committees and overseeing finance, and scientifically contributing to the multi-site studies conducted across the US and Canada by NORDIC (Neuro-Ophthalmology Research Disease Investigator Consortium).

 

I direct an ECRIP center award at NYEEI, title 'Noninvasive optical imaging detection of changes in the peripapillary retina and optic nerve head due to damage of the optic nerve' which is currently studying glaucoma, optic neuritis, NAION, giant cell arteritis, and NMO. Each project is headed by a 'fellow' who are all subspecialty trained ophthalmologists or neurologists.

New award

Publications

Selected Publications

Early Optic Nerve Head Swelling Rate Is Associated with Worsening of Visual Outcomes in Nonarteritic Anterior Ischemic Optic Neuropathy. Brian Woods, David Szanto, Jui Kai Wang, Asala Erekat, Aaron Golden, Mona K. Garvin, Zoe R. Williams, Edward F. Linton, Randy H. Kardon, Mark J. Kupersmith. Ophthalmology

From Observation to Prediction: Machine Learning Analysis of Progression of Visual loss in Nonarteritic Anterior Ischemic Optic Neuropathy. Asala N. Erekat, Zoë R. Williams, Rachelle Morgenstern, David Szanto, Michael Wall, Neil R. Miller, Leonard A. Levin, Brian Woods, Mark J. Kupersmith. American Journal of Ophthalmology

Progression of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Occurs Early and Is Unassociated With Modifiable Risk Factors. ZOË R. WILLIAMS, RACHELLE MORGENSTERN, ASALA N. EREKAT, DAVID SZANTO, MICHAEL WALL, NEIL R. MILLER, LEONARD A. LEVIN, BRIAN WOODS, MARK J. KUPERSMITH, Fraser Clare, Chen Celia, Shuey Neil, Colley Stephen, Ningli WANG, Hongliang DOU, Yong ZHONG, Luosheng TANG, Quanhong HAN, Sandner Dirk, Gamulescu Maria-Andreea, Eter Nicole, Wilhelm Helmut, Lorenz Katrin, Krishna G. Santhosh, Kekunnaya Ramesh, S. Ambika, Sharma Kumudini, Vivekanand Uttamrao Warkad, Saxena Rohit, Kumar S. Mahesh, Das Dipankar, Hegade Atul, Mazumdar Shahana, Daighavane Sachin, Sachdeva Virender, Kalish Hadas, Klein Ainat, Huna Baron Ruth, Leiba Hana, Goldenberg Cohen Nitza, Shneck Marina, Kruger Joshua, Ciardella Antonio Pasquale, Virgili Gianni, Carta Arturo, Bianchi Marzoli Stefania, Sharon Tow, Chin Chee Fang, MacIntosh Peter, Bennett Jeffrey. American Journal of Ophthalmology

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Kupersmith during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Founder/Co-Founder/Partner

  • SafeTherapeutics, LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.